Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Salix Pharmaceuticals, Ltd. (SLXP)

Q2 2012 Earnings Call

August 8, 2012 5:00 pm ET

Executives

Michael Freeman – Associate Vice President, Investor Relations and Corporate Communications

Adam C. Derbyshire – Chief Financial Officer, Executive Vice President-Finance and Administration

Carolyn J. Logan – President and Chief Executive Officer

William P. Forbes – Executive Vice President-Research and Development and Chief Development Officer

Analysts

Michael Faerm – Credit Suisse

Ami Fadia – UBS Securities LLC

Mario Corso – Caris & Co., Inc.

David A. Amsellem – Piper Jaffray, Inc.

Corey Davis – Jeffries & Co, Inc.

Jim Dawson – Buckingham Research

Annabel Samimy – Stifel, Nicolaus & Co., Inc.

Irina Rivkind – Cantor Fitzgerald Securities

Michael Tong – Wells Fargo Securities LLC

Andrew J. Finkelstein – Susquehanna Financial Group LLP

Liisa A. Bayko – JMP Securities LLC

Scott R. Henry – ROTH Capital Partners LLC

Patricia Banks – DISCERN Securities, Inc.

Gregory D. Fraser – Bank of America/Merrill Lynch

Presentation



Operator

Compare to:
Previous Statements by SLXP
» Salix Pharmaceuticals Ltd Q3 2009 Earnings Call Transcript
» Salix Pharmaceuticals, Ltd. Q4 2008 Earnings Call Transcript
» Salix Pharmaceuticals, Ltd. Q3 2008 Earnings Call Transcript

Good afternoon. My name is Jay, and I will be your conference operator today. At this time, I would like to welcome everyone to Salix Pharmaceuticals’ Second Quarter 2012 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. (Operator Instructions) Thank you.

Mr. Michael Freeman, Associate Vice President of Investor Relations, you may begin.

Michael Freeman

Thank you. Good afternoon, and thank you for joining us today. I am Mike Freeman, Associate Vice President of Investor Relations and Corporate Communications for Salix Pharmaceuticals. With me today are Carolyn Logan, President and Chief Executive Officer; Adam Derbyshire, Executive Vice President and Chief Financial Officer; and Bill Forbes, Executive Vice President, Medical and Research and Development, and Chief Development Officer.

1 2 3 Next › Last »